Professor Gili Regev-Yohai, director of the Sheba Infectious Disease Epidemiology Unit, said people who received both doses of the vaccine are more likely to be carriers of the virus and will no longer spread because of the high of antibodies they received.
This is the first indication that a Covid-19 vaccine could stop its spread.
On Monday, the hospital had vaccinated about 80 percent of its staff with the first dose – 7,106 people in total – and 4,484 with the elevation picture.
“The results of the study are consistent with the Pfizer test and even higher than expected,” said Dr. Regev-Yohai.
Although people who have been ill and recovered are still not eligible for the Pfizer vaccine in Israel, if further research shows that the vaccine produces better immunity, it is possible that they are surrounded in a second phase, at least by the elevation picture, she said.
This is one of the first studies conducted outside of Pfizer ‘s own test of vaccine efficacy.
Israel leads the world in per capita inoculations, after crossing the two million mark over the weekend.